Stock ARPO AERPIO PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Aerpio Pharmaceuticals

Equities

ARPO

US00810B1052

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Aerpio Pharmaceuticals

Aadi Bioscience Completes Merger With Aerpio Pharmaceuticals; Shares Decline on Nasdaq Debut MT
Aerpio Pharmaceuticals, Inc.(NasdaqCM:ARPO) dropped from NASDAQ Composite Index CI
Aadi Bioscience, Inc. completed the acquisition of Aerpio Pharmaceuticals, Inc. in a reverse merger transaction. CI
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
North American Morning Briefing : Stock Futures -3- DJ
AERPIO PHARMACEUTICALS : HC Wainwright Upgrades Aerpio Pharmaceuticals to Buy from Neutral on 'Transformative' Aadi Merger, Sets $22 Price Target MT
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Aerpio Pharmaceuticals : Earnings Flash (ARPO) AERPIO PHARMACEUTICALS Reports Q1 Loss $-0.09 MT
Aerpio Pharmaceuticals : Aadi Bioscience to Merge Into Combined Listed Company MT
Aadi Bioscience, Inc. agreed to acquire Aerpio Pharmaceuticals, Inc. in a reverse merger transaction. CI
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020 CI
Aerpio Pharmaceuticals Continues to Evaluate Strategic Alternatives CI
Aerpio Pharmaceuticals : Quantum Leap Healthcare to Discontinue Testing of Aerpio Pharmaceutical's Razuprotafib in COVID Trial MT
Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’S Razuprotafib in I-Spy Covid Trial CI
Aerpio Pharmaceuticals, Inc. Plans to Terminate Kevin Peters as Chief Scientific Officer and Chief Medical Officer CI
After Hours Watch List Scorecard: ISR, TATT, ARPO MT
Aerpio Pharmaceuticals Announces Strategic Review After Topline Results from Razuprotafib Glaucoma Phase 2 Trial CI
MT Newswires After Hours Watch List: ISR, TATT, ARPO MT
Aerpio Pharmaceuticals : Pharma Starts Strategic Review To Boost Shareholder Value MT
Aerpio Pharmaceuticals, Inc. Announces Strategic Review After Topline Results from Razuprotafib Glaucoma Phase 2 Trial CI
AERPIO PHARMACEUTICALS : HC Wainwright Adjusts Aerpio Pharmaceuticals' Price Target to $1.50 From $2, Keeps at Neutral MT
Aerpio Pharmaceuticals, Inc. Announces Topline Results from Razuprotafib Glaucoma Phase 2 Trial CI
Transcript : Aerpio Pharmaceuticals, Inc., Q3 2020 Earnings Call, Nov 10, 2020
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19 CI

Chart Aerpio Pharmaceuticals

Chart Aerpio Pharmaceuticals
More charts

Company Profile

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Its lead product candidate is razuprotafib. Razuprotafib, is a small molecule VE-PTP inhibitor, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. The Company is also developing a bispecific antibody that binds both VEGF and VE-PTP, which is designed to inhibit VEGF activation and activate Tie2. The Company's pipeline includes Razuprotafib (AKB-9778) Open Angle Glaucoma, Razuprotafib Acute Respiratory Distress Syndrome (ARDS)/ COVID-19, Razuprotafib Diabetic Kidney Disease, ARP-1536 Retinopathy/Nephropathy and Bispecific Ab Retinopathy/Cancer.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. ARPO Stock
  4. News Aerpio Pharmaceuticals
  5. Aerpio Pharmaceuticals : Aadi Bioscience to Merge Into Combined Listed Company